• Skip to primary navigation
  • Skip to main content
  • Skip to footer
PPi Logo 20Yrs
address
  • Home
  • About
    • Introduction
    • PPi’s 20th Anniversary
    • The Strength of PPI HC
    • Our Mission
    • Global Reach
    • Customers
    • Team
    • Gallery
  • Services
    • Landscape Assessments
    • Market Access Strategy
    • Research and Insights
    • Pricing Strategy
    • Reimbursement Strategy
    • Health Technology Assessment dossiers
    • Health Economics
    • Orphan & Rare Diseases
  • Communications
    • Case Studies
    • Publications
    • Conferences
  • Contact
  • Home
  • About
    • Introduction
    • PPi’s 20th Anniversary
    • The Strength of PPI HC
    • Our Mission
    • Global Reach
    • Customers
    • Team
    • Gallery
  • Services
    • Landscape Assessments
    • Market Access Strategy
    • Research and Insights
    • Pricing Strategy
    • Reimbursement Strategy
    • Health Technology Assessment dossiers
    • Health Economics
    • Orphan & Rare Diseases
  • Communications
    • Case Studies
    • Publications
    • Conferences
  • Contact

Orphan & Rare Diseases

  1. Home >
  2. Services >
  3. Orphan & Rare Diseases >
Orphan and Rare Disease

PPi HC helps companies developing technologies for rare diseases to optimize patient access and to maximize revenues despite challenging pricing environments and sometimes low levels of clinical evidence frequently achievable for such drugs.

Orphan drug clinical development is often challenging due to the burden of access to the targeted orphan patient population. This clinical development remains however frequently associated with (necessarily) high and challenging pricing as investment need to be recouped over relatively small patient populations where there is a high degree of unmet clinical need. PPi HC has provided support on many orphan are rare disease technologies, working with the complex issues specific to such drug development and commercialization. We provide the required expertise to optimize not only orphan disease launch adaptations but commercial and market access strategies through a combination of:

  • Primary research intelligence and market insights for orphan drugs,
  • Benchmarking of orphan drug HTA reports and price corridors,
  • In-licensing reviews,
  • Biomarker analysis,
  • Launch planning support.

Services

  • Landscape Assessments
  • Market Access Strategy
  • Research and Insights
  • Pricing Strategy
  • Reimbursement Strategy
  • Health Technology dossiers
  • Health Economics
  • Orphan & Rare Diseases

TESTIMONIALS

“With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.”

Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.

“I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.”

Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma

“I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project.”

Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals

“Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!”

Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals

PPI Logo

Adding global value through local expertise and insight

Adding global value through local expertise and insight

PPi Healthcare Consulting Ltd
5 The Chambers, Vineyard
Abingdon-on-Thames
Oxfordshire
OX14 3PX, UK

PPi 20yr Logo

Further information:
E: info@ppi.consulting
T: +44 (0)7811 363098

Privacy Policy

© copyright 2020
PPi Healthcare Consulting Ltd
All rights reserved

This website uses cookies to improve your experience. To view our privacy policy click here. To change your cookie preferences:Cookie settingsor ACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT